<qa>  What is the name of the study medication that is not blinded for patients?Rituximab and Belimumab will be administered intravenously according to the manufacturers instructions. Clinical and immunological parameters will be assessed every 8-12 weeks. The study medication is not blinded for patients nor physicians. The study intends to include 15 refractory SLE patients. 